Valeant Pharmaceuticals (NYSE:VRX) grows through acquisition, mostly through smaller accretive deals. But management had its elephant guns loaded and after missing out on generic drugmaker Actavis bagged its big game via an $8.7 billion buyout of eye-care heavyweight Bausch & Lomb.
In this video, health-care analyst David Williamson discusses why Valeant investors should be excited about adding Bausch & Lomb instead of Actavis and whether more transformative acquisitions are on the way.
Follow David on Twitter: @MotleyDavid.
The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.